180 Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

180 Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$699K	Buy	190,562 +20,880	+12%	+$69.5K	0.07%	246
2026 Q1	$521K	Buy	169,682 +76,481	+82%	+$296K	0.06%	275
2025 Q4	$381K	Buy	93,201 +36,971	+66%	+$183K	0.04%	310
2025 Q3	$274K	Buy	56,230 +16,800	+43%	+$88.2K	0.03%	381
2025 Q2	$200K	Buy	39,430 +10,665	+37%	+$52.4K	0.03%	400
2025 Q1	$152K	Sell	28,765 -2,465	-8%	-$18K	0.02%	388
2024 Q4	$211K	Buy	31,230 +5,455	+21%	+$36.7K	0.03%	383
2024 Q3	$170K	Buy	25,775 +8,320	+48%	+$59.6K	0.03%	419
2024 Q2	$134K	Buy	+17,455	New	+$152K	0.02%	413

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

180 Wealth Advisors's RXRX Position: Q2 2026 in Review

180 Wealth Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 12% in Q2 2026, buying an estimated $69.5K and bringing the position to 190,562 shares worth $699K. The position accounts for 0.07% of the portfolio, ranked #246.

180 Wealth Advisors first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

180 Wealth Advisors held 190,562 shares of Recursion Pharmaceuticals worth $699K as of Q2 2026.
180 Wealth Advisors bought 20,880 Recursion Pharmaceuticals shares in Q2 2026, an estimated $69.5K.
Recursion Pharmaceuticals made up 0.07% of 180 Wealth Advisors's portfolio in Q2 2026, its #246 holding.
180 Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.